Top Markets
Coin of the day
Tectonic Therapeutic, Inc. Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc.

TECX
Rank in Stocks #11671
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm... Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Share Price
$35.63
Last synced: 2026-08-28
Market Cap
$672.28M
Change (1 day)
-2.92%
Change (1 year)
39.50%
Country
US
Trade Tectonic Therapeutic, Inc. (TECX)

Category

Revenue for Tectonic Therapeutic, Inc. (TECX)
Revenue in Aug 2026 TTM: 0
According to Tectonic Therapeutic, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Tectonic Therapeutic, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$6.02B -
NL
$15.74B -
AU
$2.23B -
US
- -
CH